Endocrinology | Phase II Developments

Diamyd Medical AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

Outsourcing in Clinical Trials

Participation Not Confirmed

Update your events

DIAGNODE-2 Results and Meta-Analysis with Diamyd® to Be Presented at Diabetes Conference

Lead Product(s): GAD-alum,Vitamin D2

Therapeutic Area: Endocrinology Product Name: Diamyd

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 26, 2021

Details:

Results from the phase IIb trial DIAGNODE-2 with intralymphatic administration of Diamyd® and meta-analysis comprising data from more than 600 patients treated with Diamyd® showing treatment effect in individuals carrying the HLA DR3-DQ2 haplotype, will be presented.

Oramed Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Outsourcing in Clinical Trials

Participation Not Confirmed

Update your events

Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study

Lead Product(s): Insulin

Therapeutic Area: Endocrinology Product Name: ORMD-0801

Highest Development Status: Phase II Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 21, 2021

Details:

Randomization of patients in Oramed's first Phase 3 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D) is under way. The study is being conducted in accordance with U.S. Food and Drug Administration (FDA) approved protocols.

Poxel

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Outsourcing in Clinical Trials

Participation Not Confirmed

Update your events

Poxel Regains Imeglimin Rights From Metavant

Lead Product(s): Imeglimin Hydrochloride

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Metavant Sciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Terminated January 14, 2021

Details:

Metavant will return all rights to Imeglimin to Poxel, as well as all data, materials, and information, including FDA regulatory filings, related to the program. Metavant is not entitled to any payment from Poxel as part of the return of the program.